Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist

British Journal of Pharmacology

Volumn 137, Issue 4, 2002, Pages 449-458

  Behm, David J ^a   Herold, Christopher L ^a   Ohlstein, Eliot H ^a   Knight, Steven D ^a   Dhanak, Dashyant ^a   Douglas, Stephen A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Carbachol; Endothelin 1; GPR14; SB 710411; Sodium nitroprusside; Somatostatin; Urotensin II; UT receptor; Vasoconstriction; Vasorelaxation

Indexed keywords

CELL SURFACE RECEPTOR; CYCLOPEPTIDE; G PROTEIN COUPLED RECEPTOR; SB 710411; SB-710411; UROTENSIN; UROTENSIN II; UTS2R PROTEIN, HUMAN; 4 CHLOROPHENYLALANINE CYCLO(DEXTRO CYSTEINYL 3 PYRIDYLALANINE DEXTRO TRYPTOPHANYLLYSYLVALYLCYSTEINE) 4 CHLOROPHENYLALANINAMIDE; ANGIOTENSIN; CARBACHOL; ENDOTHELIN 1; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; LEMAKALIM; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYLEPHRINE; POTASSIUM CHLORIDE; RECEPTOR BLOCKING AGENT; SOMATOSTATIN; SOMATOSTATIN 14; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IN VITRO STUDY; MALE; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASOCONSTRICTION; ANIMAL TISSUE; AORTA CONSTRICTION; BINDING AFFINITY; BLOOD VESSEL TONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HOMEOSTASIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AORTA, THORACIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS; VASOCONSTRICTION;

EID: 0036799374     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704887     Document Type: Article

References (23)

1. Ames, R.S., Sarau, H.M., Chambers, J.K., Willette, R.N., Aiyar, N.V., Romanic, A.M., Louden, C.S., Foley, J.J., Sauermelch, C.F., Coatney, R.W., Ao, Z., Disa, J., Holmes, S.D., Stadel, J.M., Martin, J.D., Liu, W.S., Glover, G.I., Wilson, S., McNulty, D.E., Ellis, C.E., Elshourbagy, N.A., Shabon, U., Trill, J.J., Hay, D.W.P., Ohlstein, E.H., Bergsma, D.J. & Douglas, S.A. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
2. Behm, D.J., Naselsky, D.P., Herold, C.L., Aiyar, N.V., Knight, S.D., Dhanak, D. & Douglas, S.A. (2001). Pharmacological characterization of a novel peptidic urotensin-II receptor antagonist. Pharmacologist, 43, 190.
3. Bohm, F. & Pernow, J. (2002). Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol., 135, 25-27.
4. Camarda, V., Rizzi, A., Calo, G., Gendron, G., Perron, S.I., Kostenis, E., Zamboni, P., Mascoli, F. & Regoli, D. (2002). Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn-Schmiedeberg's Arch. Pharmacol., 365, 141-149.
5. Coy, D.H., Rossowski, W.J., Cheng, B.L., Hocart, S.J. & Taylor, J.E. (2000). Novel urotensin-II (UII) antagonists point to multiple receptor involvement in UII bioactivity. Reg. Pep., 94, 48.
6. Douglas, S.A., Beck, G.R., Elliott, J.D. & Ohlstein, E.H. (1995). Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br. J. Pharmacol., 114, 1529-1540.
7. Douglas, S.A. & Ohlstein, E.H. (2000a). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med., 10, 229-237.
8. Douglas, S.A. & Ohlstein, E.H. (2000b). Urotensin Receptors. In The IUPHAR Compendium of Receptor Characterization and Classification. ed. Girdlestone, D. pp 365-372. London: IUPHAR Media.
9. Douglas, S.A., Sulpizio, A.C., Piercy, V., Sarau, H.M., Ames, R.S., Aiyar, N.V., Ohlstein, E.H. & Willette, R.N. (2000). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol., 131, 1262-1274.
10. Herold, C.L., Behm, D.J., Aiyar, N.V., Naselsky, D.P. & Douglas, S.A. (2001). The somatostatin derivative, Cpa-c-[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide, is an agonist at the human UT receptor but not the rat UT receptor in transfected HEK293 cells. Pharmacologist. 43, 189.
11. Huang, H., Lee, F., Chan, C., Chang, F., Wang, S., Lin, H., Hou, M., Chen, C., Tai, C., Lai, I., & Lee, S. (2002). Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats. J. Hepatol., 36, 163-168.
12. Leslie, S.J., Denvir, M. & Webb, D.J. (2000). Human urotensin-II causes vasoconstriction in the human skin microcirculation. Circulation, 102, II-113.
13. Long, J.B., Rigamonti, D.D., Dosaka, K., Kraimer, J.M. & Martinez-Arizala, A. (1992). Somatostatin causes vasoconstriction, reduces blood flow and increases vascular permeability in the rat central nervous system. Br. J. Pharmacol., 260, 1425-1432.
14. Maguire, J.J., Kuc, R.E. & Davenport, A.P. (2000). Orphan-receptor ligand human urotensin-II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol., 131, 441-446.
15. Paysant, J., Rupin, A., Simonet, S., Fabiani, J.N. & Verbeuren, T.J. (2001). Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam. Clin. Pharmacol., 15, 227-231.
16. Rossowski, W.J., Cheng, B.L., Taylor, J.E., Datta, R. & Coy, D.H. (2002), Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rhokinase: Inhibition by somatostatin receptor antagonists. Eur. J. Pharmacol., 438, 159-170.
17. Russell, F.D., Molenaar, P. & O'Brien, D.M., (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
18. Saetrum Opgaard, O., Nothacker, H., Ehlert, F.J. & Krause, D.N. (2000). Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol., 406, 265-271.
19. Sauzeau, V., Le Mellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P. & Loirand, G. (2001). Human urotensin II-induced contraction and arterial smooth muscle proliferation are mediated by RhoA and Rho-kinase. Circ. Res., 88, 1102-1104.
20. Tzanidis, A., Hannan, R., Thomas, W., Onan, D., Autelitano, D., See, F. & Krum, H. (2001). Increased expression of urotensin II and its receptor in an experimental model of left ventricular myocardial infarction in the rat: Implications for cardiac remodeling. European Heart Journal, 22, 141.
21. Watanabe, T., Pakala, R., Katagiri, T. & Benedict, C.R. (2001). Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 104, 16-18.
22. Wiest, R., Tsai, M.H. & Groszmann, R.J. (2001). Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology, 120, 975-983.
23. Zou, Y., Nagai, R. & Yamazaki, T. (2001). Urotensin-II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett., 508, 57-60.